Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 12/20 | 0.60 |
| ▸ | MAOA | P21397 | 9/20 | 0.51 |
| ▸ | MAOB | P27338 | 9/20 | 0.51 |
| ▸ | NAMPT | P43490 | 2/20 | 0.50 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | RCOR1 | Q9UKL0 | 3/20 | 0.47 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15789046 | 1.00 | KDM1A (0.60) | KDM1AMAOAMAOBNAMPTMCHR1 | |
| SCHEMBL15789149 | 0.90 | KDM1A (0.58) | KDM1AMAOAMAOBMCHR1RCOR1 | |
| SCHEMBL14701062 | 0.90 | KDM1A (0.58) | KDM1AMAOAMAOBMCHR1RCOR1 | |
| SCHEMBL15789279 | 0.83 | KDM1A (0.65) | KDM1AMAOAMAOBPTPN1RCOR1 | |
| SCHEMBL14701019 | 0.83 | KDM1A (0.65) | KDM1AMAOAMAOBPTPN1RCOR1 | |
| SCHEMBL14701029 | 0.83 | KDM1A (0.65) | KDM1AMAOAMAOBPTPN1RCOR1 | |
| SCHEMBL15789361 | 0.83 | KDM1A (0.65) | KDM1AMAOAMAOBPTPN1RCOR1 | |
| SCHEMBL15789089 | 0.78 | KDM1A (0.70) | KDM1AMAOAMAOBPTPN1RCOR1 | |
| SCHEMBL15789086 | 0.78 | KDM1A (0.70) | KDM1AMAOAMAOBPTPN1RCOR1 | |
| SCHEMBL15789026 | 0.76 | KDM1A (0.74) | KDM1AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2743256-B1 | CYCLOPROPANEAMINE COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-06-27 | — | — | EP | disclosed |
| EP-2743256-B1 | CYCLOPROPANEAMINE COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-06-27 | — | — | EP | disclosed |
| US-9682925-B2 | Cyclopropaneamine compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-06-20 | — | — | US | disclosed |
| US-20160130215-A1 | CYCLOPROPANEAMINE COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-05-12 | — | — | US | disclosed |
| US-9278931-B2 | Cyclopropaneamine compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-03-08 | — | — | US | disclosed |
| US-20140228405-A1 | CYCLOPROPANEAMINE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-14 | — | — | US | disclosed |
| EP-2743256-A1 | CYCLOPROPANEAMINE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2014-06-18 | — | — | EP | disclosed |
| WO-2013022047-A1 | CYCLOPROPANEAMINE COMPOUND | 武田薬品工業株式会社 (JP) | 2013-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130215-A1 | CYCLOPROPANEAMINE COMPOUND | KDM1A, KDM1B, KDM3A | KDM1A 1/4885MAOA 101/4885MAOB 90/4885 |
| US-20140228405-A1 | CYCLOPROPANEAMINE COMPOUND | KDM1A, KDM1B, KDM3A | KDM1A 1/4885MAOA 101/4885MAOB 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.